A MDP Model for Breast and Ovarian Cancer Intervention Strategies for BRCA1/2 Mutation Carriers

被引:15
|
作者
Abdollahian, Mehrnaz [1 ]
Das, Tapas K. [1 ]
机构
[1] Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL 33620 USA
关键词
BRCA1/2; mutations; hereditary breast and ovarian cancer; intervention strategies; Markov decision process (MDP); COST-EFFECTIVENESS; PREVENTION STRATEGIES; DECISION-ANALYSIS; WOMEN; SURVIVAL; SURGERY; RISK; TOOL;
D O I
10.1109/JBHI.2014.2319246
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Purpose: Women with BRCA1/2 mutations have higher risk for breast and ovarian cancers. Available intervention actions include prophylactic surgeries and breast screening, which vary significantly in cost, cancer prevention, and in resulting death from other causes. We present a model designed to yield optimal intervention strategies for mutation carriers between the ages of 30 and 65 and any prior intervention history. Methods: A Markov decision process (MDP) model is developed that considers yearly state transitions for the mutation carriers and state dependent intervention actions. State is defined as a vector comprising mutation type, health states, prior intervention actions, and age. A discounted value iteration algorithm is used to obtain optimal strategies from the MDP model using both cost and quality-adjusted life years (QALYs) as rewards. Results: The results from MDP model show that for 30-year-old women with BRCA1 mutation and no prior intervention history, the cost-optimal strategy is a combination of prophylactic mastectomy (PM) and prophylactic oophorectomy (PO) at age 30 with no screening afterwards. Whereas, the QALYs-optimal strategy suggests PO at age 30 and PM at age 50 with screening afterwards. For BRCA2 mutation carriers at age 30, the cost-optimal strategy is PO at age 30, PM at age 40, and yearly screening only after age 56. Corresponding QALYs-optimal strategy is PM at age 40 with screening. Strategies for all other ages (31 to 65) are obtained and presented. It is also demonstrated that the cost-optimal strategies offer near maximum survival rate and near minimum cancer incidence rates by age 70, when compared to other ad hoc strategies.
引用
收藏
页码:720 / 727
页数:8
相关论文
共 50 条
  • [1] Future possibilities in the prevention of breast cancer -: Intervention strategies in BRCA1 and BRCA2 mutation carriers
    Eeles, RA
    BREAST CANCER RESEARCH, 2000, 2 (04) : 283 - 290
  • [2] Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
    Rosalind A Eeles
    Breast Cancer Research, 2
  • [3] Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    Hopper, John L.
    Barnes, Daniel R.
    Phillips, Kelly-Anne
    Mooij, Thea M.
    Roos-Blom, Marie-Jose
    Jervis, Sarah
    van Leeuwen, Flora E.
    Milne, Roger L.
    Andrieu, Nadine
    Goldgar, David E.
    Terry, Mary Beth
    Rookus, Matti A.
    Easton, Douglas F.
    Antoniou, Antonis C.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2402 - 2416
  • [4] Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Antoniou, Antonis C.
    ENDOCRINE-RELATED CANCER, 2016, 23 (10) : T69 - T84
  • [5] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Osorio, Ana
    Ramon y Cajal, Teresa
    Baiget, Montserrat
    Lasa, Adriana
    Diaz-Rubio, Eduardo
    de la Hoya, Miguel
    Caldes, Trinidad
    Teule, Alex
    Lazaro, Conxi
    Blanco, Ignacio
    Balmana, Judith
    Sanchez-Olle, Gessami
    Vega, Ana
    Blanco, Ana
    Chirivella, Isabel
    Esteban Cardenosa, Eva
    Duran, Mercedes
    Velasco, Eladio
    Martinez de Duenas, Eduardo
    Tejada, Maria-Isabel
    Miramar, Maria-Dolores
    Calvo, Maria-Teresa
    Guillen-Ponce, Carmen
    Salazar, Raquel
    San Roman, Carlos
    Urioste, Miguel
    Benitez, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232
  • [6] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Roger L. Milne
    Ana Osorio
    Teresa Ramón y Cajal
    Montserrat Baiget
    Adriana Lasa
    Eduardo Diaz-Rubio
    Miguel de la Hoya
    Trinidad Caldés
    Alex Teulé
    Conxi Lázaro
    Ignacio Blanco
    Judith Balmaña
    Gessamí Sánchez-Ollé
    Ana Vega
    Ana Blanco
    Isabel Chirivella
    Eva Esteban Cardeñosa
    Mercedes Durán
    Eladio Velasco
    Eduardo Martínez de Dueñas
    María-Isabel Tejada
    María-Dolores Miramar
    María-Teresa Calvo
    Carmen Guillén-Ponce
    Raquel Salazar
    Carlos San Román
    Miguel Urioste
    Javier Benítez
    Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
  • [7] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Leendert H Zaaijer
    Helena C van Doorn
    Marian J E Mourits
    Marc van Beurden
    Joanne A de Hullu
    Muriel A Adank
    Luc R C W van Lonkhuijzen
    Hans F A Vasen
    Brigitte F M Slangen
    Katja N Gaarenstroom
    Ronald P Zweemer
    Peggy M L H Vencken
    Caroline Seynaeve
    Mieke Kriege
    British Journal of Cancer, 2016, 115 : 1174 - 1178
  • [8] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Zaaijer, Leendert H.
    van Doorn, Helena C.
    Mourits, Marian J. E.
    van Beurden, Marc
    de Hullu, Joanne A.
    Adank, Muriel A.
    van Lonkhuijzen, Luc R. C. W.
    Vasen, Hans F. A.
    Slangen, Brigitte F. M.
    Gaarenstroom, Katja N.
    Zweemer, Ronald P.
    Vencken, Peggy M. L. H.
    Seynaeve, Caroline
    Kriege, Mieke
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178
  • [9] IMPACT OF PREGNANCY ON THE RISK OF BREAST AND OVARIAN CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS
    Russo, M.
    Corvetto, E.
    Fais, M.
    Candotti, G.
    Locati, V.
    Proto, A.
    Angioni, S.
    Carcassi, C.
    Mais, V.
    Peiretti, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A391 - A391
  • [10] Management of breast cancer in BRCA1/2 mutation carriers
    Eeles, RA
    Camplejohn, R
    Peacock, J
    McMillan, T
    DISEASE MARKERS, 1999, 15 (1-3) : 204 - 204